Trial Profile

A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva HandiHaler, 18 microg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Sep 2013 Results for the effect of tiotropium bromide on spontaneous expiratory flow-volume curves presented at the 23rd Annual Congress of the European Respiratory Society.
05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
31 Aug 2012 Results will be presented at the 2012 European Respiratory Society Congress according to a Boehringer Ingelheim media release. Results were also summarised in the media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com